160 related articles for article (PubMed ID: 30297119)
1. Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors.
Lu W; Xiong H; Chen Y; Wang C; Zhang H; Xu P; Han J; Xiao S; Ding H; Chen Z; Lu T; Wang J; Zhang Y; Yue L; Liu YC; Zhang C; Yang Y; Jiang H; Chen K; Zhou B; Luo C
Bioorg Med Chem; 2018 Nov; 26(20):5397-5407. PubMed ID: 30297119
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
[TBL] [Abstract][Full Text] [Related]
3. Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.
Wu F; Hua Y; Kaochar S; Nie S; Lin YL; Yao Y; Wu J; Wu X; Fu X; Schiff R; Davis CM; Robertson M; Ehli EA; Coarfa C; Mitsiades N; Song Y
J Med Chem; 2020 May; 63(9):4716-4731. PubMed ID: 32314924
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
[TBL] [Abstract][Full Text] [Related]
5. A novel cell-permeable, selective, and noncompetitive inhibitor of KAT3 histone acetyltransferases from a combined molecular pruning/classical isosterism approach.
Milite C; Feoli A; Sasaki K; La Pietra V; Balzano AL; Marinelli L; Mai A; Novellino E; Castellano S; Tosco A; Sbardella G
J Med Chem; 2015 Mar; 58(6):2779-98. PubMed ID: 25730130
[TBL] [Abstract][Full Text] [Related]
6. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.
Bowers EM; Yan G; Mukherjee C; Orry A; Wang L; Holbert MA; Crump NT; Hazzalin CA; Liszczak G; Yuan H; Larocca C; Saldanha SA; Abagyan R; Sun Y; Meyers DJ; Marmorstein R; Mahadevan LC; Alani RM; Cole PA
Chem Biol; 2010 May; 17(5):471-82. PubMed ID: 20534345
[TBL] [Abstract][Full Text] [Related]
7. Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity.
Shirakawa K; Wang L; Man N; Maksimoska J; Sorum AW; Lim HW; Lee IS; Shimazu T; Newman JC; Schröder S; Ott M; Marmorstein R; Meier J; Nimer S; Verdin E
Elife; 2016 May; 5():. PubMed ID: 27244239
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors.
Liu R; Zhang Z; Yang H; Zhou K; Geng M; Zhou W; Zhang M; Huang X; Li Y
Eur J Med Chem; 2019 Oct; 180():171-190. PubMed ID: 31306905
[TBL] [Abstract][Full Text] [Related]
9. Identification of long chain alkylidenemalonates as novel small molecule modulators of histone acetyltransferases.
Sbardella G; Castellano S; Vicidomini C; Rotili D; Nebbioso A; Miceli M; Altucci L; Mai A
Bioorg Med Chem Lett; 2008 May; 18(9):2788-92. PubMed ID: 18434144
[TBL] [Abstract][Full Text] [Related]
10. Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents.
Yang H; Pinello CE; Luo J; Li D; Wang Y; Zhao LY; Jahn SC; Saldanha SA; Chase P; Planck J; Geary KR; Ma H; Law BK; Roush WR; Hodder P; Liao D
Mol Cancer Ther; 2013 May; 12(5):610-20. PubMed ID: 23625935
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors.
Yang Y; Zhang R; Li Z; Mei L; Wan S; Ding H; Chen Z; Xing J; Feng H; Han J; Jiang H; Zheng M; Luo C; Zhou B
J Med Chem; 2020 Feb; 63(3):1337-1360. PubMed ID: 31910017
[TBL] [Abstract][Full Text] [Related]
12. Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112.
Zucconi BE; Luef B; Xu W; Henry RA; Nodelman IM; Bowman GD; Andrews AJ; Cole PA
Biochemistry; 2016 Jul; 55(27):3727-34. PubMed ID: 27332697
[TBL] [Abstract][Full Text] [Related]
13. Current development of CBP/p300 inhibitors in the last decade.
He ZX; Wei BF; Zhang X; Gong YP; Ma LY; Zhao W
Eur J Med Chem; 2021 Jan; 209():112861. PubMed ID: 33045661
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines.
Santer FR; Höschele PP; Oh SJ; Erb HH; Bouchal J; Cavarretta IT; Parson W; Meyers DJ; Cole PA; Culig Z
Mol Cancer Ther; 2011 Sep; 10(9):1644-55. PubMed ID: 21709130
[TBL] [Abstract][Full Text] [Related]
15. An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells.
Gu ML; Wang YM; Zhou XX; Yao HP; Zheng S; Xiang Z; Ji F
Oncol Rep; 2016 Nov; 36(5):2763-2770. PubMed ID: 27633918
[TBL] [Abstract][Full Text] [Related]
16. Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.
Picaud S; Fedorov O; Thanasopoulou A; Leonards K; Jones K; Meier J; Olzscha H; Monteiro O; Martin S; Philpott M; Tumber A; Filippakopoulos P; Yapp C; Wells C; Che KH; Bannister A; Robson S; Kumar U; Parr N; Lee K; Lugo D; Jeffrey P; Taylor S; Vecellio ML; Bountra C; Brennan PE; O'Mahony A; Velichko S; Müller S; Hay D; Daniels DL; Urh M; La Thangue NB; Kouzarides T; Prinjha R; Schwaller J; Knapp S
Cancer Res; 2015 Dec; 75(23):5106-5119. PubMed ID: 26552700
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells.
Yan G; Eller MS; Elm C; Larocca CA; Ryu B; Panova IP; Dancy BM; Bowers EM; Meyers D; Lareau L; Cole PA; Taverna SD; Alani RM
J Invest Dermatol; 2013 Oct; 133(10):2444-2452. PubMed ID: 23698071
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP.
Nie S; Wu F; Wu J; Li X; Zhou C; Yao Y; Song Y
Eur J Med Chem; 2022 Jul; 237():114407. PubMed ID: 35512565
[TBL] [Abstract][Full Text] [Related]
19. Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP/p300 Acetylome.
Weinert BT; Narita T; Satpathy S; Srinivasan B; Hansen BK; Schölz C; Hamilton WB; Zucconi BE; Wang WW; Liu WR; Brickman JM; Kesicki EA; Lai A; Bromberg KD; Cole PA; Choudhary C
Cell; 2018 Jun; 174(1):231-244.e12. PubMed ID: 29804834
[TBL] [Abstract][Full Text] [Related]
20. Live-cell studies of p300/CBP histone acetyltransferase activity and inhibition.
Dancy BM; Crump NT; Peterson DJ; Mukherjee C; Bowers EM; Ahn YH; Yoshida M; Zhang J; Mahadevan LC; Meyers DJ; Boeke JD; Cole PA
Chembiochem; 2012 Sep; 13(14):2113-21. PubMed ID: 22961914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]